{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:06:09Z","timestamp":1791655569348,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM007739"],"award-info":[{"award-number":["T32GM007739"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10549-020-05726-y","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T08:36:41Z","timestamp":1593592601000},"page":"227-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Dermatologic adverse events related to the PI3K\u03b1 inhibitor alpelisib (BYL719) in patients with breast cancer"],"prefix":"10.1007","volume":"183","author":[{"given":"Diana G.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce M.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria S.","family":"Blinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline F.","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela R.","family":"Drullinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Funt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal L.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana E.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanu","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A.","family":"Traina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda T.","family":"Vahdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-3710","authenticated-orcid":false,"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"5726_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/bcr3039","volume":"13","author":"TW Miller","year":"2011","unstructured":"Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224","journal-title":"Breast Cancer Res"},{"issue":"10","key":"5726_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1200\/JCO.2017.74.8301","volume":"36","author":"D Zardavas","year":"2018","unstructured":"Zardavas D, Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O\u2019Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S (2018) Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data. J Clin Oncol 36(10):981\u2013989. https:\/\/doi.org\/10.1200\/JCO.2017.74.8301","journal-title":"J Clin Oncol"},{"issue":"3","key":"5726_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J (2018) The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34(3):427\u2013438. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.008","journal-title":"Cancer Cell"},{"issue":"20","key":"5726_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Papai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D, Group S-S (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"issue":"2","key":"5726_CR5","doi-asserted-by":"publisher","first-page":"e184475","DOI":"10.1001\/jamaoncol.2018.4475","volume":"5","author":"D Juric","year":"2019","unstructured":"Juric D, Janku F, Rodon J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS (2019) Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol 5(2):e184475. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4475","journal-title":"JAMA Oncol"},{"key":"5726_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO","volume":"36","author":"D Juric","year":"2018","unstructured":"Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Blumenstein L, Coughlin C, Quadt C, Baselga J (2018) Phosphatidylinositol 3 kinase alpha-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first in-human study. J Clin Oncol 36:1\u20139. https:\/\/doi.org\/10.1200\/JCO","journal-title":"J Clin Oncol"},{"issue":"1","key":"5726_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","volume":"23","author":"IA Mayer","year":"2017","unstructured":"Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL (2017) A phase Ib study of alpelisib (BYL719), a PI3Kalpha-specific inhibitor, with Letrozole in ER+\/HER2- metastatic breast cancer. Clin Cancer Res 23(1):26\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0134","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5726_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/cas.13923","volume":"110","author":"Y Ando","year":"2019","unstructured":"Ando Y, Iwasa S, Takahashi S, Saka H, Kakizume T, Natsume K, Suenaga N, Quadt C, Yamada Y (2019) Phase I study of alpelisib (BYL719), an alpha-specific PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci 110(3):1021\u20131031. https:\/\/doi.org\/10.1111\/cas.13923","journal-title":"Cancer Sci"},{"issue":"1","key":"5726_CR9","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/j.clbc.2014.09.003","volume":"15","author":"J Sheu","year":"2015","unstructured":"Sheu J, Hawryluk EB, Litsas G, Thakuria M, LeBoeuf NR (2015) Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor. Clin Breast Cancer 15(1):e77\u201381. https:\/\/doi.org\/10.1016\/j.clbc.2014.09.003","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"5726_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","volume":"68","author":"T Shiohara","year":"2019","unstructured":"Shiohara T, Mizukawa Y (2019) Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int 68(3):301\u2013308. https:\/\/doi.org\/10.1016\/j.alit.2019.03.006","journal-title":"Allergol Int"},{"issue":"1","key":"5726_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19(1):31\u201339. https:\/\/doi.org\/10.1007\/s40257-018-0384-3","journal-title":"Am J Clin Dermatol"},{"key":"5726_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/ijd.12205","volume":"53","author":"JL Curry","year":"2014","unstructured":"Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG (2014) Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol 53:376\u2013384","journal-title":"Int J Dermatol"},{"issue":"17","key":"5726_CR13","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1016\/j.bmcl.2012.07.042","volume":"22","author":"I Bruce","year":"2012","unstructured":"Bruce I, Akhlaq M, Bloomfield GC, Budd E, Cox B, Cuenoud B, Finan P, Gedeck P, Hatto J, Hayler JF, Head D, Keller T, Kirman L, Leblanc C, Le Grand D, McCarthy C, O'Connor D, Owen C, Oza MS, Pilgrim G, Press NE, Sviridenko L, Whitehead L (2012) Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway. Bioorg Med Chem Lett 22(17):5445\u20135450. https:\/\/doi.org\/10.1016\/j.bmcl.2012.07.042","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"5726_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3):282\u2013290. https:\/\/doi.org\/10.1200\/JCO.2011.36.1360","journal-title":"J Clin Oncol"},{"issue":"7","key":"5726_CR15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/s1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J, Im S-A, Iwata H, Cort\u00e9s J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagie\u0142\u0142o-Gruszfeld A, Pistilli B, Tseng L-M, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M (2017) Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(7):904\u2013916. https:\/\/doi.org\/10.1016\/s1470-2045(17)30376-5","journal-title":"Lancet Oncol"},{"issue":"11","key":"5726_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008\u20131018. https:\/\/doi.org\/10.1056\/NEJMoa1314583","journal-title":"N Engl J Med"},{"issue":"16","key":"5726_CR17","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, OBrien SM, Stilgenbauer S, (2019) Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients with Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol 37(16):1391\u20131402. https:\/\/doi.org\/10.1200\/JCO.18","journal-title":"J Clin Oncol"},{"issue":"10","key":"5726_CR18","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","volume":"27","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Pena C, Xia C, Reif S, Genvresse I, Ramanathan RK (2016) First-in-human phase I study of copanlisib (BAY 80\u20136946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol 27(10):1928\u20131940. https:\/\/doi.org\/10.1093\/annonc\/mdw282","journal-title":"Ann Oncol"},{"issue":"35","key":"5726_CR19","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, Leppa S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Ozcan M, Kosinova M, Bouabdallah K, Sieidel H, Pena C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL (2017) Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 35(35):3898\u20133905. https:\/\/doi.org\/10.1200\/JCO.2017.75.4648","journal-title":"J Clin Oncol"},{"issue":"8","key":"5726_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM (2018) Activity of the PI3K-delta-gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131(8):888\u2013898","journal-title":"Blood"},{"issue":"23","key":"5726_CR21","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M, Nagy Z, Illes A, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S (2018) The phase 3 Duo trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood 132(23):2446\u20132455","journal-title":"Blood"},{"issue":"8","key":"5726_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","volume":"131","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S (2018) Duvelisib, a novel oral dual inhibitor of PI3K-delta, gamma, is clinically active in advanced hematologic malignancies. Blood 131(8):877\u2013887","journal-title":"Blood"},{"issue":"23","key":"5726_CR23","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Montillo M, Nagy Z, Illes A, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Stilgenbauer S (2018) The Phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood 132(23):2446\u20132455","journal-title":"Blood"},{"issue":"4","key":"5726_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (2017) The PI3K pathway in human disease. Cell 170(4):605\u2013635. https:\/\/doi.org\/10.1016\/j.cell.2017.07.029","journal-title":"Cell"},{"issue":"7719","key":"5726_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"560","author":"BD Hopkins","year":"2018","unstructured":"Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR, Bareja R, Ma Y, Harris EM, Sboner A, Beltran H, Rubin MA, Mukherjee S, Cantley LC (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560(7719):499\u2013503. https:\/\/doi.org\/10.1038\/s41586-018-0343-4","journal-title":"Nature"},{"key":"5726_CR26","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1073\/pnas.96.4.1563","volume":"96","author":"K Podsypanina","year":"1999","unstructured":"Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R (1999) Mutations of Pten\/Mmac1 in mice causes neoplasia in multiple organ systems. PNAS 96:1563\u20131568","journal-title":"PNAS"},{"issue":"11","key":"5726_CR27","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41556-018-0218-9","volume":"20","author":"Z Ying","year":"2018","unstructured":"Ying Z, Sandoval M, Beronja S (2018) Oncogenic activation of PI3K induces progenitor cell differentiation to suppress epidermal growth. Nat Cell Biol 20(11):1256\u20131266. https:\/\/doi.org\/10.1038\/s41556-018-0218-9","journal-title":"Nat Cell Biol"},{"issue":"38","key":"5726_CR28","doi-asserted-by":"publisher","first-page":"32856","DOI":"10.1074\/jbc.M506119200","volume":"280","author":"E Calautti","year":"2005","unstructured":"Calautti E, Li J, Saoncella S, Brissette JL, Goetinck PF (2005) Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem 280(38):32856\u201332865. https:\/\/doi.org\/10.1074\/jbc.M506119200","journal-title":"J Biol Chem"},{"issue":"3","key":"5726_CR29","first-page":"283","volume":"2","author":"S Stevenson","year":"2007","unstructured":"Stevenson S, Thronton J (2007) Effect of estrogens on skin aging and the potential of SERMs. Clin Interv Aging 2(3):283\u2013297","journal-title":"Clin Interv Aging"},{"issue":"17","key":"5726_CR30","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-16-2888","volume":"23","author":"D Juric","year":"2017","unstructured":"Juric D, de Bono JS, LoRusso PM, Nemunaitis J, Heath EI, Kwak EL, Macarulla Mercade T, Geuna E, Jose de Miguel-Luken M, Patel C, Kuida K, Sankoh S, Westin EH, Zohren F, Shou Y, Tabernero J (2017) A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3Kalpha Isoform Inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 23(17):5015\u20135023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2888","journal-title":"Clin Cancer Res"},{"key":"5726_CR31","doi-asserted-by":"crossref","unstructured":"Hong R, Edgar K, Song K, Steven S, Young A, Hamilton P, Arrazate A, De La Cruz C, Chan C, Pang J, Salphati L, Belvin M, Nannini M, Staben S, Friedman L, Sampath D (2018) Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas","DOI":"10.1158\/1538-7445.SABCS17-PD4-14"},{"key":"5726_CR32","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3389\/fimmu.2018.01873","volume":"9","author":"EB Thangam","year":"2018","unstructured":"Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, Church MK, Saluja R (2018) The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol 9:1873. https:\/\/doi.org\/10.3389\/fimmu.2018.01873","journal-title":"Front Immunol"},{"issue":"4","key":"5726_CR33","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/s0091-6749(03)01878-5","volume":"112","author":"A Togias","year":"2003","unstructured":"Togias A (2003) H1-receptors: Localization and role in airway physiology and in immune functions. J Allergy Clin Immunol 112(4):S60\u2013S68. https:\/\/doi.org\/10.1016\/s0091-6749(03)01878-5","journal-title":"J Allergy Clin Immunol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05726-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:16:07Z","timestamp":1624925767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05726-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5726"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05726-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"10 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DGW declares no conflicts of interest. DMB declares no conflicts of interest. VSB declares consulting\/advisory agreements with Pfizer and Anthem Foundation. VSB receives research funding from the NIH (5 R37 CA214785). JFB declares no conflicts of interest. PRD declares no conflicts of interest. SAF receives research funding from Genentech\/Roche, AstraZeneca, and Decibel Therapeutics. SAF has stock\/equity ownership in Urogen Pharma, Allogene Therapeutics, Kronos Bio, Vida Ventures, Kite Pharma, and Neogene Therapeutics. KLJ declares consulting\/advisory board roles with Novartis, Spectrum Pharmaceuticals, ADC Therapeutics, Pfizer, BMS, Abbvie, AstraZeneca, Jounce Therapeutics, Taiho, Oncology, Genentech, Synthon, Lilly Pharmaceuticals, and Intellisphere. KLJ receives research funding from Novartis, Clovis Oncology, Genentech, Astra Zeneca, ADC Therapeutics, Novita Pharmaceuticals, Debio Pharmaceuticals, Pfizer, Lilly Pharmaceuticals, Zymeworks, Immunomedics, and Puma Biotechnology. DEL declares no conflicts of interest. TL declares no conflicts of interest. SM declares consulting\/advisory agreements with Daiichi Sankyo, Carrick, Eli Lilly, Genentech, MacroGenics, and GSK Speakers Bureau Genetech. SM receives research support from Novartis, Genentech, Astra Zeneca\/ MedImmune, Seattle Genetics, and Daiichi Sankyo. PR declares a consulting\/advisory agreement with Novartis. PR receives institutional research support from Illumina and GRAIL. MS is an employee of Novartis. TAT declares consulting\/advisory agreements with Genentech\/Roche, Pfizer, AstraZeneca, Merck, Puma, Advaxis, Celgene, Innocrin, Genomic Health, Bristol-Myers Squibb, Samsung, Athenex, Aduro Biotech, Halozyme, Daiichi Sankyo, Ionis. TT receives research funding from Eisai, Pfizer, Novartis, Innocrin, AstraZeneca, Astellas, Immunomedics, Genentech, Daiichi, and Carrick. LTV declares no conflicts of interest. MEL declares a consulting\/advisory agreement with Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our retrospective research study was approved by and in accordance with the ethical standards of Memorial Sloan Kettering Cancer Center\u2019s Institutional Review Board committee (Protocol # 16-458). This article does not contain any studies with human or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}